GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mega Lifesciences PCL (BKK:MEGA-F) » Definitions » ROC (Joel Greenblatt) %

Mega Lifesciences PCL (BKK:MEGA-F) ROC (Joel Greenblatt) % : 44.43% (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Mega Lifesciences PCL ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Mega Lifesciences PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 44.43%.

The historical rank and industry rank for Mega Lifesciences PCL's ROC (Joel Greenblatt) % or its related term are showing as below:

BKK:MEGA-F' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 22.93   Med: 37.91   Max: 60.83
Current: 48.12

During the past 13 years, Mega Lifesciences PCL's highest ROC (Joel Greenblatt) % was 60.83%. The lowest was 22.93%. And the median was 37.91%.

BKK:MEGA-F's ROC (Joel Greenblatt) % is ranked better than
86.31% of 1059 companies
in the Drug Manufacturers industry
Industry Median: 8.16 vs BKK:MEGA-F: 48.12

Mega Lifesciences PCL's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 9.80% per year.


Mega Lifesciences PCL ROC (Joel Greenblatt) % Historical Data

The historical data trend for Mega Lifesciences PCL's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Lifesciences PCL ROC (Joel Greenblatt) % Chart

Mega Lifesciences PCL Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.17 37.60 51.83 60.83 47.90

Mega Lifesciences PCL Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.86 49.62 54.26 44.11 44.43

Competitive Comparison of Mega Lifesciences PCL's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Mega Lifesciences PCL's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mega Lifesciences PCL's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mega Lifesciences PCL's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Mega Lifesciences PCL's ROC (Joel Greenblatt) % falls into.



Mega Lifesciences PCL ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3313.753 + 3377.379 + 428.347) - (4104.774 + 83.916 + 128.097)
=2802.692

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3006.84 + 3123.205 + 349.608) - (3702.181 + 0 + 128.95)
=2648.522

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Mega Lifesciences PCL for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2214.436/( ( (2225.287 + max(2802.692, 0)) + (2291.824 + max(2648.522, 0)) )/ 2 )
=2214.436/( ( 5027.979 + 4940.346 )/ 2 )
=2214.436/4984.1625
=44.43 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mega Lifesciences PCL  (BKK:MEGA-F) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Mega Lifesciences PCL ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Mega Lifesciences PCL's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Lifesciences PCL (BKK:MEGA-F) Business Description

Traded in Other Exchanges
Address
Debaratna Road, 909, Ample Tower, 9th Floor, Bangna Nuea,Bangna, Bangkok, THA, 10260
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins and fast-moving consumer goods as well as the provides distribution services relating to such products. The company's products portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins and fast moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purpose and sale of goods manufactured by third parties; and OEM.

Mega Lifesciences PCL (BKK:MEGA-F) Headlines

No Headlines